Gilead’s 4-in-1 Stribild HIV Pill Wins U.S. FDA Approval
This article is for subscribers only.
Gilead Sciences Inc., the world’s biggest maker of AIDS drugs, won U.S. approval to sell a pill for new HIV patients that combines four of the company’s drugs into one.
The therapy, called Stribild, was cleared as a medicine that will help simplify patients’ treatment regimens, the U.S. Food and Drug Administration said yesterday in a statement. Stribild contains two new drugs and two previously approved compounds that make up Foster City, California-based Gilead’s Truvada HIV medicine.